- Home
- NPKI vs URGN Comparison
NPKI vs URGN Comparison
Compare NPKI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPKI
- URGN
- Stock Information
- Founded
- NPKI 1932
- URGN 2004
- Country
- NPKI United States
- URGN United States
- Employees
- NPKI N/A
- URGN N/A
- Industry
- NPKI Metal Fabrications
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- NPKI Industrials
- URGN Health Care
- Exchange
- NPKI Nasdaq
- URGN Nasdaq
- Market Cap
- NPKI 940.6M
- URGN 830.4M
- IPO Year
- NPKI N/A
- URGN 2017
- Fundamental
- Price
- NPKI $12.37
- URGN $17.73
- Analyst Decision
- NPKI Strong Buy
- URGN Strong Buy
- Analyst Count
- NPKI 3
- URGN 8
- Target Price
- NPKI $12.17
- URGN $28.50
- AVG Volume (30 Days)
- NPKI 678.6K
- URGN 1.1M
- Earning Date
- NPKI 10-30-2025
- URGN 11-11-2025
- Dividend Yield
- NPKI N/A
- URGN N/A
- EPS Growth
- NPKI N/A
- URGN N/A
- EPS
- NPKI N/A
- URGN N/A
- Revenue
- NPKI $234,741,000.00
- URGN $94,238,000.00
- Revenue This Year
- NPKI $19.94
- URGN $39.63
- Revenue Next Year
- NPKI $9.36
- URGN $111.49
- P/E Ratio
- NPKI N/A
- URGN N/A
- Revenue Growth
- NPKI 6.96
- URGN 10.85
- 52 Week Low
- NPKI $4.76
- URGN $3.42
- 52 Week High
- NPKI $12.39
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- NPKI 73.20
- URGN 50.80
- Support Level
- NPKI $11.41
- URGN $16.37
- Resistance Level
- NPKI $11.79
- URGN $17.64
- Average True Range (ATR)
- NPKI 0.31
- URGN 0.88
- MACD
- NPKI 0.09
- URGN 0.11
- Stochastic Oscillator
- NPKI 98.80
- URGN 69.13
About NPKI NPK International Inc. Common Stock
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.